依非韦伦致男性乳房发育1例分析

doi:10.19803/j.1672-8629.20230041

中国药物警戒 ›› 2023, Vol. 20 ›› Issue (11): 1306-1308.
DOI: 10.19803/j.1672-8629.20230041

依非韦伦致男性乳房发育1例分析

唐炯¹, 刘颖^2,*

¹成都市第七人民医院,成都医学院附属肿瘤医院药剂科,四川成都 610213;
²成都市第三人民医院药学部,四川成都 610031

收稿日期:2023-01-29 出版日期:2023-11-15 发布日期:2023-11-13
通讯作者: ^*刘颖,女,硕士,主管药师,临床药学。E-mail: yingliu0208@sina.com
作者简介:唐炯,男,硕士,临床药师,临床药学。

One case of gynecomastia induced by efavirenz tablets

TANG Jiong¹, LIU Ying^2,*

¹Department of Pharmacy, Chengdu Seventh People’s Hospital, Affiliated Cancer Hospital of Chengdu Medical College, Chengdu Sichuan 610213, China;
²Department of Pharmacy, The Third People’s Hospital of Chengdu, Affiliated Hospital of Southwest Jiaotong University, Chengdu Sichuan 610031, China

Received:2023-01-29 Online:2023-11-15 Published:2023-11-13

摘要/Abstract

摘要： 目的探讨非核苷类反转录酶抑制剂依非韦伦致男性乳房发育病例,为临床预防及处理其不良反应提供参考。方法分析1例感染人类免疫缺陷病毒（HIV）男性患者服用依非韦伦导致乳房发育的治疗过程,探讨依非韦伦致乳腺增生的机理并排除其他药物的可能性。结果患者服用依非韦伦后单侧乳房发育,停用该药并予以手术治疗2个月后,乳房不适减轻。结论依非韦伦致男性乳房发育或与影响雌激素/雄激素的作用有关,用药期间应定期做乳房检查,做到早识别、早处理。

关键词: 依非韦伦, 男性乳房发育, 人类免疫缺陷病毒, 获得性免疫缺陷综合征, 药品不良反应, 抗逆转录病毒治疗, 非核苷逆转录酶抑制剂

Abstract: Objective To explore one case of gynecomastia induced by efavirenz, and to provide reference for clinical prevention and treatment of the adverse reactions. Methods The process of treating one patient who had developed gynecomastia after taking efavirenz was analyzed in order to investigate the mechanism by which efavirenz caused gynecomastia and to rule out the possibility of other drugs. Results The patient developed unilateral gynecomastia after taking efaveranz. The breast discomfort was alleviated 2 months after withdrawal of efaveran and surgical treatment. Conclusion Gynecomastia caused by efavirenz may be related to the effect of estrogen/androgen. During medication, breasts should be examined regularly for the sake of early identification and treatment.

Key words: efavirenz, gynecomastia, HIV, AIDS, adverse drug reactions, antiretroviral therapy, non-nucleoside reverse transcriptase inhibitors

中图分类号:

R978
R994.11

唐炯, 刘颖. 依非韦伦致男性乳房发育1例分析[J]. 中国药物警戒, 2023, 20(11): 1306-1308.

TANG Jiong, LIU Ying. One case of gynecomastia induced by efavirenz tablets[J]. Chinese Journal of Pharmacovigilance, 2023, 20(11): 1306-1308.

参考文献

[1] HE N.New progress of AIDS epidemiology in China[J]. Chinese Journal of Disease Control and Prevention(中华疾病控制杂志), 2021, 25(12): 1365-1368, 1480.
[2] National Center for AIDS/STD Control and Prevention, China CDC. National handbook on free anti-HIV drug for AIDS treatment[M]. 4th ed, Beijing:People’s Medical Publishing House, 2016.
[3] BASTOS MM, COSTA CCP, BEZERRA TC, et al.Efavirenz a nonnucleoside reverse transcriptase inhibitor of first-generation: approaches based on its medicinal chemistry[J]. European Journal of Medicinal Chemistry, 2016, 47(13): 455-465.
[4] Acquired Immunodeficiency Syndrome and Hepatitis C Professional Group, Society of Infectious Diseases,Chinese Medical Association, Chinese Center for Disease Control and Prevention. Chinese guidelines for diagnosis and treatment of human immunodeficiency virus infection/acquired immunodeficiency syndrome (2021 edition)[J]. Medical Journal of Peking Union Medical College Hospital(协和医学杂志), 2022, 13(2): 203-226.
[5] CAO MX, HUANG L, FENG YF.Literature analysis of adverse reactions caused by Efavirenz[J] . Clinical Medication Journal(临床药物治疗杂志), 2021,19(3): 31-35.
[6] ABAH IO, AKABI M, ABAH ME, et al.Incidence and predictors of adverse drug events in an African cohort of HIV-infected adults treated with efavirenz[J]. GERMS, 2015, 5(3): 83-91.
[7] JOVER F, CUADRADO JM, ROIG P, et al.Efavirenz-associated gynecomastia: report of five cases and review of the literature[J].The Breast Journal, 2004, 10(3): 244-246.
[8] SAKA B, AKAKPO AS, BASSOWA A, et al.Non-nucleoside reverse transcriptase inhibitors (NNRTIs)-induced Stevens-Johnson syndrome and gynecomastia in an HIV-infected child: a case report[J]. Annales de dermatologie et de venereologie, 2018, 145(12): 773-776.
[9] WANG YY.The specificity of incidence and therapy amidst HIV-infectied patients with breast cancer[D]. Chongqing: Chongqing Medical University, 2019.
[10] ZHANG LJ, TU YY.Nursing experience of a male breast cancer patient with AIDS[J]. Electronic Journal of Clinical Medical Literature(临床医药文献电子杂志), 2020, 7(54): 164-165.
[11] D’ANDREA F, CECCARELLI M, FACCIOL À, et al. Breast cancer in women living with HIV[J]. European Review for Medical and Pharmacological Sciences, 2019, 23(3): 1158-1164.
[12] NARANJO CA, BUSTO U, SELLERSe EM, et al.A method for estimating the probability of adverse drug reactions[J]. Clinical Pharmacology and Therapeutics, 1981, 30(2): 239-245.
[13] EVANS DL, PANTANOWITZ L, DEZUBE BJ, et al.Breast enlargement in 13 men who were seropositive for human immunodeficiency virus[J]. Clinical Infectious Diseases, 2002, 35(9): 1113-1119.
[14] QAZI NA, MORLESE JF, KING DM, et al.True gynaecomastia, another manifestation of immune reconstitution disease?[J].International Journal of STD & AIDS, 2002, 13(1): 59-65.
[15] KANAKIS GA, NORDKAP L, BANG AK, et al.EAA clinical practice guidelines-gynecomastia evaluation and management[J]. Andrology, 2019, 7(6): 778-793.
[16] OUYANG Y, ZHONG C, XIA C, et al.One case of breast hyperplasia caused by digoxin tablets[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2023, 20(3): 346-347, 359.
[17] OSMAN S, MANSOOR E, BUCCIMAZZA I.Gynaecomastia in the durban breast unit: a comparison of HIV- and non-HIV-infected Individuals[J]. World Journal of Surgery, 2020, 44(5): 1538-1546.

依非韦伦致男性乳房发育1例分析

One case of gynecomastia induced by efavirenz tablets

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	贾晋生, 刘红亮, 王青, 侯永芳, 李馨龄. 基于知识图谱联合ERNIE-DPCNN模型的药品不良反应自动关联性评价方法研究[J]. 中国药物警戒, 2024, 21(2): 163-166.
[2]	李应芬, 韩雷. 319例注射用脑蛋白水解物药品不良反应报告分析[J]. 中国药物警戒, 2024, 21(2): 195-198.
[3]	徐伟佳, 彭崎, 黄海渝, 张磊姣, 肖华, 吴雪. 285例新型抗肿瘤药物不良反应分析[J]. 中国药物警戒, 2024, 21(2): 199-203.
[4]	郭清华, 彭笑笑, 朱萍, 刘西霖, 杨颖华, 陈志海. 氨氯地平过量致多器官功能障碍综合征1例分析[J]. 中国药物警戒, 2024, 21(2): 204-207.
[5]	方美琳, 郑慧敏, 王存泽, 王凌, 阮君山. 注射用奥沙利铂致全身肌肉疼痛1例分析[J]. 中国药物警戒, 2024, 21(2): 208-210.
[6]	陈玉艳, 张明霞, 张涛, 张晋. 斯鲁利单抗注射液致间质性肺炎不良反应1例分析[J]. 中国药物警戒, 2024, 21(2): 213-215.
[7]	曹桂萍, 邓琳琳, 朱干红, 陆颖, 马爽, 陈玲玲, 刘丽丽. 天麻首乌片致严重肝损伤1例分析[J]. 中国药物警戒, 2024, 21(2): 216-218.
[8]	高云娟, 赵旭, 白天凯, 柏兆方, 王伽伯, 宋海波, 肖小河. 基于不良反应监测大数据的药品安全风险发现与识别策略[J]. 中国药物警戒, 2024, 21(1): 1-5.
[9]	郭龙鑫, 高云娟, 吴承钊, 龙敏娟, 祝胜凯, 宋海波, 赵旭, 肖小河. 基于不良反应监测大数据的中药药源性肝损伤风险信号新发现及易感因素初探[J]. 中国药物警戒, 2024, 21(1): 15-19.
[10]	蒋文硕, 杨莉. 694例癫痫医师药师联合门诊患者药品不良反应分析[J]. 中国药物警戒, 2024, 21(1): 102-106.
[11]	陈华炎, 江东波, 郭春连, 杨家琪, 黎雨欣, 蔡伟明. 326例奈玛特韦片/利托那韦片治疗新型冠状病毒感染安全性分析[J]. 中国药物警戒, 2024, 21(1): 107-110.
[12]	刘赛月, 吕小琴, 周耘. 疑似药品不良反应死亡病例调查及报告实施要点[J]. 中国药物警戒, 2023, 20(9): 971-974.
[13]	里筱竹, 王蔷, 逄瑜, 张轶菁. 个例药品不良反应报告管理浅析与思考[J]. 中国药物警戒, 2023, 20(9): 975-977.
[14]	逄瑜, 刘博, 吕少俐, 王涛, 邢颖, 秦星宇, 田月洁, 吴文宇. 基于国际药物警戒经验探讨收集患者报告的意义[J]. 中国药物警戒, 2023, 20(9): 978-981.
[15]	刘文东, 崔欢欢, 王晓晗, 苏娴, 王海学. 我国儿童用药临床试验期间药物警戒监管体系现状及思考[J]. 中国药物警戒, 2023, 20(9): 1002-1006.